FDA Considers Splitting Jynneos Vaccine Into Fifths for Monkeypox

The FDA is looking into possibly splitting doses of Bavarian Nordic’s Jynneos vaccine into fifths to inoculate individuals 18 years and older against monkeypox in order to address inadequate supplies.

Using the “dose-sparing” approach, a single-dose vial would be used to administer up to five separate doses. The proposed method also involves injecting the reduced Jynneos doses in between layers of skin, creating a pocket for the vaccine.

If the method works, the vaccine would still be administered at two doses 28 days apart.

Jynneos is currently approved for the prevention of smallpox and monkeypox in adults 18 years and older determined to be at high risk for smallpox or monkeypox infection.